Axsome Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Axsome Therapeutics
AXSM Stock  USD 186.27  2.02  1.10%   
Axsome Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Axsome Therapeutics' valuation are provided below:
Gross Profit
515.6 M
Profit Margin
(0.41)
Market Capitalization
9.3 B
Enterprise Value Revenue
16.4504
Revenue
561.3 M
There are over one hundred nineteen available fundamental signals for Axsome Therapeutics, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to validate Axsome Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 2nd of February 2026, Market Cap is likely to grow to about 3.4 B. Also, Enterprise Value is likely to grow to about 3.2 B

Axsome Therapeutics Total Revenue

465.72 Million

Check Axsome Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Axsome Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.6 M, Interest Expense of 7.9 M or Selling General Administrative of 374.5 M, as well as many indicators such as Price To Sales Ratio of 11.48, Dividend Yield of 0.0 or PTB Ratio of 67.19. Axsome financial statements analysis is a perfect complement when working with Axsome Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Axsome Stock
Check out the analysis of Axsome Therapeutics Correlation against competitors.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

Axsome Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets686.5 M653.8 M204.3 M
Slightly volatile
Short and Long Term Debt Total233 M221.9 M65 M
Slightly volatile
Other Current Liabilities185.8 M177 M41.2 M
Slightly volatile
Total Current Liabilities277.9 M264.6 M66.4 M
Slightly volatile
Accounts Payable86.9 M82.8 M21.9 M
Slightly volatile
Cash380.8 M362.7 M134.1 M
Slightly volatile
Cash And Short Term Investments380.8 M362.7 M134.1 M
Slightly volatile
Common Stock Total Equity2.7 K4.3 K2.5 K
Slightly volatile
Common Stock Shares Outstanding31.5 M55.1 M26.7 M
Slightly volatile
Other Current Assets14.5 M13.8 M3.3 M
Slightly volatile
Total Liabilities617.6 M588.2 M152.8 M
Slightly volatile
Total Current Assets585.7 M557.8 M177.5 M
Slightly volatile
Short Term Debt3.1 M2.9 M2.2 M
Pretty Stable
Common Stock3.3 K5.8 K2.8 K
Slightly volatile
Other Liabilities37.6 M35.8 M22.8 M
Slightly volatile
Current Deferred Revenue12.4 M11.8 M5.7 M
Slightly volatile
Non Current Assets Total100.7 M95.9 M26.7 M
Slightly volatile
Non Currrent Assets Other22.4 M21.3 M5.3 M
Slightly volatile
Long Term Debt218.2 M207.8 M61.5 M
Slightly volatile
Non Current Liabilities Total339.8 M323.6 M88.1 M
Slightly volatile
Short and Long Term Debt2.2 M2.3 M2.9 M
Slightly volatile
Property Plant And Equipment Net7.2 M6.9 M1.9 M
Slightly volatile
Property Plant And Equipment Gross7.2 M6.9 M1.9 M
Slightly volatile
Property Plant Equipment1.4 M1.3 M400.6 K
Slightly volatile
Long Term Debt Total59.3 M56.5 M26.7 M
Slightly volatile
Capital Surpluse264.6 M488.5 M228.6 M
Slightly volatile
Net Invested Capital174.7 M273.4 M112.1 M
Slightly volatile
Net Working Capital167.3 M293.2 M108.2 M
Slightly volatile
Capital Stock4.5 K5.8 K3.7 K
Slightly volatile
Capital Lease Obligations14.8 M14.1 M4.1 M
Slightly volatile
Non Current Liabilities Other54.1 M105.4 M23.1 M
Slightly volatile

Axsome Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization9.6 M9.2 M2.9 M
Slightly volatile
Interest Expense7.9 M7.6 M3.1 M
Slightly volatile
Selling General Administrative374.5 M356.7 M89.7 M
Slightly volatile
Other Operating Expenses804.5 M766.2 M198.2 M
Slightly volatile
Research Development225.9 M215.1 M61.6 M
Slightly volatile
Total Operating Expenses764.3 M727.9 M189.8 M
Slightly volatile
Interest Income1.2 M1.4 M1 M
Slightly volatile
Reconciled Depreciation9.6 M9.2 M2.3 M
Slightly volatile
Selling And Marketing Expenses65.1 M116.4 M24.6 M
Slightly volatile

Axsome Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation102.9 M98 M25.6 M
Slightly volatile
Begin Period Cash Flow466.3 M444.1 M125 M
Slightly volatile
Total Cash From Financing Activities99.5 M66.5 M74.2 M
Slightly volatile
End Period Cash Flow380.8 M362.7 M134.1 M
Slightly volatile
Depreciation9.6 M9.2 M2.3 M
Slightly volatile
Issuance Of Capital Stock44.6 M46.9 M59 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio11.4812.0950.7144
Slightly volatile
Days Sales Outstanding197155246
Slightly volatile
Average Payables24.5 M23.3 M11.6 M
Slightly volatile
Stock Based Compensation To Revenue0.440.250.6438
Slightly volatile
Capex To Depreciation0.0930.09792.6947
Slightly volatile
EV To Sales11.1411.7248.9881
Slightly volatile
Inventory Turnover1.341.911.3371
Slightly volatile
Days Of Inventory On Hand252198281
Slightly volatile
Payables Turnover0.440.420.1419
Slightly volatile
Sales General And Administrative To Revenue0.890.920.8319
Slightly volatile
Research And Ddevelopement To Revenue0.740.561.0119
Slightly volatile
Capex To Revenue8.0E-48.0E-40.011
Slightly volatile
Cash Per Share6.225.923.2406
Slightly volatile
Days Payables Outstanding86290783.4 K
Slightly volatile
Income Quality0.810.510.7304
Slightly volatile
Intangibles To Total Assets0.150.120.1899
Slightly volatile
Current Ratio2.32.423.9231
Very volatile
Receivables Turnover1.842.441.5944
Slightly volatile
Capex Per Share0.00440.00510.0043
Slightly volatile
Revenue Per Share4.067.242.4298
Slightly volatile
Interest Debt Per Share3.943.751.5387
Slightly volatile
Debt To Assets0.630.390.7665
Slightly volatile
Operating Cycle449353527
Slightly volatile
Days Of Payables Outstanding86290783.4 K
Slightly volatile
Ebt Per Ebit1.161.181.085
Slightly volatile
Long Term Debt To Capitalization0.860.871.4232
Slightly volatile
Total Debt To Capitalization1.010.891.0991
Slightly volatile
Quick Ratio2.232.353.9018
Very volatile
Net Income Per E B T1.161.151.0753
Slightly volatile
Cash Ratio1.51.583.6497
Very volatile
Days Of Inventory Outstanding252198281
Slightly volatile
Days Of Sales Outstanding197155246
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9846
Slightly volatile
Fixed Asset Turnover38.3958.1745.0775
Pretty Stable
Debt Ratio0.630.390.7665
Slightly volatile
Price Sales Ratio11.4812.0950.7144
Slightly volatile
Asset Turnover0.340.610.2383
Slightly volatile
Gross Profit Margin0.720.820.8828
Slightly volatile

Axsome Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.4 B3.3 B1.5 B
Slightly volatile
Enterprise Value3.2 B3.1 B1.4 B
Slightly volatile

Axsome Fundamental Market Drivers

Forward Price Earnings344.8276
Cash And Short Term Investments315.4 M

Axsome Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Axsome Therapeutics Financial Statements

Axsome Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Axsome Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue11.8 M12.4 M
Total Revenue443.5 M465.7 M
Cost Of Revenue38.3 M40.2 M
Stock Based Compensation To Revenue 0.25  0.44 
Sales General And Administrative To Revenue 0.92  0.89 
Research And Ddevelopement To Revenue 0.56  0.74 
Revenue Per Share 7.24  4.06 
Ebit Per Revenue(0.65)(0.69)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
How To Invest In Axsome
Details
Is Axsome Stock a good investment?
Details
What is Axsome Therapeutics' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Axsome Therapeutics Correlation against competitors.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(4.64)
Revenue Per Share
11.402
Quarterly Revenue Growth
0.632
Return On Assets
(0.20)
Return On Equity
(2.75)
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY